50 Chapter 2 Supplement 2 - (continued) First author Year Country N Disease group Age (min) Age (max) Used method* Setting Hanghoj [101] 2020 Denmark 12 Oncology 16 29 1 Intervention development Happ [102] 2013 United States 11 Cystic Fibrosis 10 16 1 Clinical care Hart [103] 2020 United Kingdom 18 Oncology 17 26 1 Clinical care / research Hein [104] 2015 The Netherlands 35 Multiple disease groups 8 16 1 Research Heiney [105] 1991 United States NR Oncology 13 22 2,8 Clinical care Hellier [106] 1986 United States 20 Radiology 5 11 1 Clinical care Hentinen [107] 1996 Finland 51 Diabetes 13 17 1 Clinical care Hoffman [108] 2019 United States 21 Ear, nose and throat disorders 6 12 1 Intervention development Horstman [109] 2002 United Kingdom 50 Multiple disease groups 6 10 1,3 Clinical care Hsiao [110] 2007 United States 20 Palliative care 9 21 1 Clinical care Huby [111] 2017 United Kingdom 26 Kidney diseases 5 17 1 Intervention development Huijer [112] 2013 Lebanon 85 Oncology 7 18 1 Clinical care Hutton [113] 2005 Australia 7 Multiple disease groups 13 18 1,3 Clinical care Ingersgaard [114] 2017 Denmark 5 Oncology 14 19 1 Research Jamalimoghadam [115] 2019 Iran 16 Multiple disease groups 12 18 1 Clinical care Jamalimoghadam [116] 2019 Iran 13 Multiple disease groups 12 18 1 Clinical care Jedeloo [117] 2010 The Netherlands 31 Multiple disease groups 12 19 1 Clinical care Jelbert [118] 2010 United Kingdom 5 Chronic Fatigue Syndrome 13 18 1 Clinical care Jeschke [119] 2020 Germany 101 Epilepsy 6 17 1 Clinical care Jiang [120] 2020 Australia 14 Juvenile Idiopathic Arthritis 15 23 1 Clinical care Jibb [121] 2017 Canada 16 Oncology 12 18 1,8 Intervention development Johnson [122] 2008 United States 27 Kidney diseases NR NR 1 Clinical care Jolley [123] 1992 United Kingdom 20 Surgery NR NR 7 Clinical care Jones [124] 2001 United States 8 Multiple disease groups 13 17 2 Research Jordan [125] 2019 United States 19 Multiple disease groups 13 19 1 Clinical care
RkJQdWJsaXNoZXIy MTk4NDMw